

CHANGE TO THE 2023 CORPORATE EVENTS CALENDAR

Naples, March 30th 2023

Farmacosmo S.p.A. ("Company", "Farmacosmo"), a company active in the Health, Pharma & Beauty sector, listed on the Euronext Growth Milan market of Borsa Italiana, announces that the Board of Directors, which met today as scheduled in the calendar of corporate events published by the Company last January 30th, resolved to postpone to March 31st, 2023 the date of the Board of Directors meeting called to express its opinion on the approval of Farmacosmo's draft financial statements and of consolidated financial statements for the financial year ending December 31st, 2022.

It is specified that this postponement was necessary in order to allow the completion of the preparation of the relevant draft financial statements, by the subsidiaries of Farmacosmo, which were acquired in the second half of last fiscal year. In this regard, the Company points out that the last acquisition transaction was completed on December 20th, 2022, and that fiscal year 2022 is the first fiscal year in relation to which the Company is required to provide the consolidated financial statements.

The Board of Directors has already been reconvened for the date of March 31st, 2023, in order to deliberate on the review and approval of Farmacosmo's draft annual financial statements and the consolidated financial statements as of December 31st, 2022, as well as the convocation of the shareholders' meeting, in first and single call, for the date of May 2nd, 2023.

The Calendar of Corporate Events for the current fiscal year, originally published by the Company on January 30th, 2023, is hereby amended and re-published as follows.

It is also announced that today the Company updated its KID (Key Information Document) regarding the "Warrant Farmacosmo 2022-2025", code ISIN IT0005487415.

The KID is available on the Company website at the following address: www.farmacosmoinvestors.com

This press release is available on the www.farmacosmoinvestors.com website, section "Investors/Press Releases" and on the authorized storage mechanism "eMarket Storage" (www.emarketstorage.com).

THE SOCIETY

Farmacosmo is a company active in the Health, Pharma & Beauty sectors. The company's business model is based on the circular model of the I(ea)n strategy, and is divided into three main business areas: Logistics, Intelligence and Node. Logistics: enables the management and fulfillment of up to 12,000 orders per day, with delivery times of up to 20 hours from carrier picking and just-in time procurement ('zero warehouse' policy). Intelligence: includes strategy definition, competitive positioning and customer journey activities, which enabled the company to intercept c. 188,000 customers in 2021. Recurring customers contributed 74% of the annual retail stream turnover. The average cart value of active customers in the retail stream amounted to €92 (€109 related to recurring customers). Node: R&D activities, process innovation and IT infrastructure of the company. Over the past five years, Farmacosmo's sales value has grown by 54% (CAGR 2016-2021) and will be around €58 million in 2021. The Farmacosmo ecosystem aims to pursue standards of excellence in every part of its value chain, being inspired by compliance with ESG principles at all stages of the logistics process (from the packaging used for online orders to carbon compensation initiatives) and in the valorisation of its employees, the company's strategic asset. The portals PerfumieriaWeb, Phàrmasi, Bau Cosmesi and ContactU, an innovative platform of telepsychology launched in March 2023, are part of Farmacosmo Group. During 2022, Farmacosmo launched its rooting strategy through the acquisition of Farmacosmo-branded logistics pharmacies. Farmacosmo's commitment to ESG is also underlined by the publication of its Sustainability Report 2021.

IDENTIFICATION CODES

Ordinary Share: ISIN IT0005487670 (Ticker COSMO)

Warrant Farmacosmo 2022-2025: ISIN IT0005487415 (Ticker WCOSMO)

FARMACOSMO+

PRESS RELEASE

FOR FURTHER INFORMATIONS:

INVESTOR RELATIONS MANAGER

Farmacosmo

Via Crispi, 51 - 80121 Napoli

Tel. +39 02 50042143

Paolo Cimmino ir@farmacosmo.it

EURONEXT GROWTH ADVISOR

Illimity Bank

Via Soperga, 9 - 20124 Milano

Tel. +39 02 82849699

farmacosmo@illimity.com

INVESTOR & MEDIA RELATIONS ADVISOR

IR Top Consulting

Via Bigli, 19 - 20121 Milano

Tel. +39 02 45473883

Pietro Autelitano ir@irtop.com

Domenico Gentile ufficiostampa@irtop.com